Health Canada Clarifies Expectations for Class III and IV Medical Device Licence Applications
Health Canada has issued a notice to industry on the information submitted with Class III and IV medical device licence applications, dated 16 July 2026.
The notice explains that Health Canada has recently observed a significant increase in the volume of information submitted with these applications.
According to the authority, including large amounts of unnecessary information can delay the review process.
Expectations for Application Content
Health Canada advises applicants to submit only the information needed to support their application.
The notice states that this helps meet regulatory requirements and supports a timely review.
If the relevance of submitted information is unclear, Health Canada may request clarification from the applicant.
Health Canada also warns that unnecessary or duplicative information can increase review times and delay the licensing process.
Summaries and Supporting Evidence
The notice reminds applicants that, under the Medical Devices Regulations, applications for Class III and IV licences must include summaries of the studies and evidence submitted.
Applicants should provide clear and concise summaries, ensure that summaries accurately reflect the supporting data and clearly identify the information required to support a timely review.
Use of Artificial Intelligence Tools
Health Canada also addresses the use of artificial intelligence tools.
Where applicants use AI tools to generate summaries or explanatory material, they remain responsible for ensuring that the content is accurate and reflects the supporting data.
Impact on Medical Device Manufacturers
For medical device manufacturers submitting Class III or IV licence applications in Canada, the notice reinforces the importance of focused, well-structured and relevant submission content.
Manufacturers should pay particular attention to:
avoiding unnecessary or duplicative information;
ensuring the relevance of all submitted evidence is clear;
preparing concise and accurate study summaries;
aligning summaries with the underlying supporting data;
reviewing AI-generated content carefully before submission;
anticipating clarification requests where relevance is unclear;
structuring applications to support an efficient review process.
For manufacturers, the notice highlights that submission quality is not only about volume of evidence, but also about relevance, clarity and accuracy.
